Active ingredientLasmiditanCat. No. P-L022-001CAS 439239-90-4Family · Pharmaceutical analytical standards
Lasmiditan
The first of the 'ditans', selective agonists of the serotonin 5-HT1F receptor: approved in the United States in 2019 and in the European Union in 2022 for the acute treatment of migraine. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Unlike many triptans, which also act on 5-HT1B and 5-HT1D receptors, it binds selectively to the 5-HT1F subtype alone: the FDA considers it a first-in-class medicine.
Go to the active ingredient →Active ingredientLasmiditanCat. No. P-L022-001CAS 439239-90-4
Isotopically labelledLasmiditan Impurity 12-13C-d2Cat. No. P-L022-002
Isotopically labelledLasmiditan-13C-d2Cat. No. P-L022-003
Impurity2,4,6-Trifluorobenzoic acidCat. No. P-L022-004CAS 28314-80-9
ImpurityLasmiditan Impurity 1Cat. No. P-L022-005CAS 613678-03-8
ImpurityLasmiditan Impurity 2Cat. No. P-L022-006CAS 517875-04-6
Active ingredientLasmiditan HemisuccinateCat. No. P-L022-007CAS 439239-92-6
ImpurityLasmiditan Impurity 3Cat. No. P-L022-008
ImpurityLasmiditan Impurity 4Cat. No. P-L022-010
ImpurityLasmiditan Impurity 5Cat. No. P-L022-011
ImpurityLasmiditan Impurity 6Cat. No. P-L022-012
ImpurityLasmiditan Impurity 7Cat. No. P-L022-013
ImpurityLasmiditan Impurity 8Cat. No. P-L022-014
ImpurityLasmiditan Impurity 9Cat. No. P-L022-015
ImpurityLasmiditan Impurity 10Cat. No. P-L022-016
ImpurityLasmiditan N-OxideCat. No. P-L022-017
ImpurityLasmiditan Impurity 11Cat. No. P-L022-018CAS 547724-14-1No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.